Refine by
In Vivo Studies Articles & Analysis
45 news found
Endotoxin free silver nanoparticles are characterized by high purity and low endotoxin levels, ideal for use in in vivo studies and clinical trials with a low risk of adverse effects. ...
Introduction Intraoperative irrigation is a commonly used method aimed at reducing microbial burden by removing tissue debris, metabolic waste, and tissue exudate from the surgical field prior to site closure.1 With the absence of universally established standard of care and robust clinical data, the selection of appropriate irrigation solution remains a topic of debate. Isotonic saline has ...
This critical step in the drug development process refers to the systematic evaluation of the safety of therapeutic drugs through laboratory studies and animals in vitro. Alfa Chemistry has established a drug safety evaluation system that meets international standards, helping clients to shorten the experimental time and reduce the cost as well. ...
The therapeutic product would be administered and be designed to mitigate risks of antibiotic-resistant infections in resource constrained settings such as battlefield medicine and trauma care. Preclinical in vivo studies demonstrate Lumen’s therapeutic approach could be effective in preventing and treating infections caused by antibiotic resistant ...
” At the meetings, the company presented data from IND-enabling studies demonstrating the safety and pharmacokinetic profile of OLX-07010 in in vitro and in vivo preclinical studies. ...
DESCRIPTION provided by applicant Heart disease is the leading cause of death for both men and women in the US accounting for nearly of all annual deaths A high cholesterol level is well known risk factors for heart disease Although blood cholesterol can be lowered using a number of marketed drugs of which statins are the leading drugs only of patients taking these drugs are achieving the low ...
Targeting neurodegenerative diseases such as Alzheimer’s, Huntington’s and Parkinson’s Identified two lead cannabinoid analog compounds for in vivo studies NSERC grant funding supports InMed’s collaborative research projects with Dr. ...
After digestion, the amino acid sequence may undergo further amino acid modifications and be metabolized by hepatic P450 enzymes. In vivo metabolite studies of protein/peptide drugs usually focus on non-specific enzymatic cleavage or modification of amino acids, P450 enzyme metabolism, and multi-charge distribution. ...
In addition, the presentation will discuss how the resulting antibody-drug conjugates (ADCs) Araris is able to develop show favorable biophysical properties and demonstrate potent activity at very low doses in multiple in-vivo head-to-head studies with a significant improvement in therapeutic index. ...
Presentation highlights: Araris’ anti-Nectin-4 antibody-drug conjugate (ADC) showed superior activity to enfortumabvedotin (Padcev®, EV) in head-to-head in vitro and in vivo studies Araris’ linker technology was used to generate a highly homogenous and pure ADC within 24 hours with enfortumab as the targeting antibody and monomethyl auristatin ...
“The study results also established the compatibility and utility of the continuous ambulatory infusion device with our proprietary subcutaneous formulation. ...
Following the successful completion of the R&D project in 30th September 2016 (supported by a Smart award from the Innovate UK (TSB), Arterius has recently been awarded further funding from the Biomedical Catalyst-Early Stage programme to conduct the In-vitro and In-vivo GLP Evaluation of the Novel Bioresorbable Coronary Scaffolds; ArterioSorb. ...
AFM28 induced potent, effective, and specific anti-tumor activity against CD123-positive cells irrespective of mutational status Study demonstrated specific anti-tumor response even at low levels of CD123 expression with no evidence for off-target cytotoxic activity towards CD123-negative healthy bone marrow progenitors In vivo studies of an ...
Details about the Abstracts The AFM24 monotherapy study (NCT 04259450) abstract includes information about the dose-escalation phase of the study. ...
Pedro Lichtinger, Chairman and CEO, said, “The planned Phase 1b/2 clinical study is expected to establish efficacy in multiple myeloma; based on the response rates observed in our preclinical studies we believe STAR-LLD will provide a highly efficacious treatment option in newly diagnosed multiple ...
Phase 1 clinical trial." The multicenter Phase 1 study will consist of a monotherapy cohort, a combination therapy cohort, and a dose expansion cohort to evaluate the safety, tolerability, pharmacokinetics, and efficacy of IO-108 alone and in combination with pembrolizumab. The Chinese study will also confirm the recommended Phase 2 dose selected from the U.S. ...
Crown Bioscience and HUB led the design of the experiments which were executed using the high content screening platform from Crown Bioscience using HUB Organoids. These studies enabled the discrimination of antibodies that were active against a broad range of mutational profiles and tumor subtypes, with hit validation and mechanism of action studies that enabled ...
ViGeneron has worked on this program together with Daiichi Sankyo since early 2021.This follow-on collaboration allows the companies to create and validate vgAAV-based therapeutic candidates for the undisclosed target through in-vivo animal studies. Through a unique and stringent in vivo selection procedure, where an AAV2-based peptide-display ...
“Our ADCs have the potential to address current challenges seen amongst other currently approved ADC therapies, such as stability and solubility issues, in addition to being able to display favorable biophysical properties. We are looking forward to studying our linker technology further and continuing to advance our anti-CD79b antibody ...
“Our ADCs have the potential to address current challenges seen amongst other currently approved ADC therapies, such as stability and solubility issues, in addition to being able to display favorable biophysical properties. We are looking forward to studying our linker technology further and continuing to advance our anti-CD79b antibody ...